DMRADamora Therapeutics, Inc.
Is it safe?
Mostly sound, with a caveat: insiders buying, but heavy debt (CCC) and big price swings.
Insiders were net buyers (+$253K, 90 days to Oct 8, 2026). SEC Form 4 filings: officers and directors must report their own trades within two business days.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -99% · now 38% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can DMRA take a bad year?
The deepest fall in DMRA's price history on file is −99%; it is 38% below its high today.
Worst drawdown on file · −38% today
- Annualised volatility
- 343%
Annualised volatility · three times the market's own swing
Details›
- Cash and short-term investments
- $541M
- EBITDA, trailing twelve months
- −$271M
- Operating profit, trailing twelve months
- −$271M
- Annualised volatilitytwo years of daily moves
- 343%
- Worst drawdown on file
- −99%
- Below its 52-week high
- 38%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.